Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication.

It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).

[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.

[3] is indicated for the control of absence seizures that are refractory to other drugs.

[2] This anticonvulsant-related article is a stub.